


---

## Increasing Therapeutic Benefit of Innovative Pharmaceuticals

Share of new molecular entities rated as an innovative pharmaceutical or significant therapeutic improvement (in percent)

---



---

Source: Arzneimittelverordnungs-Report 2009, Fricke

Of the 122 molecular entities that received marketing authorization in Germany for the first time over the last four years, 90 (74 percent) were rated as innovations or therapeutically relevant improvements – even by critical experts. The share of new molecular entities that can be considered innovative in this respect has continuously increased over the past 19 years.